Literature DB >> 33917906

Understand KRAS and the Quest for Anti-Cancer Drugs.

Chang Woo Han1, Mi Suk Jeong2, Se Bok Jang3.   

Abstract

The KRAS oncogene is mutated in approximately ~30% of human cancers, and the targeting of KRAS has long been highlighted in many studies. Nevertheless, attempts to target KRAS directly have been ineffective. This review provides an overview of the structure of KRAS and its characteristic signaling pathways. Additionally, we examine the problems associated with currently available KRAS inhibitors and discuss promising avenues for drug development.

Entities:  

Keywords:  KRAS; cancer; inhibitors; signaling pathway

Year:  2021        PMID： 33917906     DOI： 10.3390/cells10040842

Source DB:  PubMed          Journal:  Cells        ISSN： 2073-4409            Impact factor:   6.600


  3 in total

1.  Genetic landscape of pancreatic adenocarcinoma patients: a pilot study from Pakistan.

Authors:  Saleema Mehboob Ali; Yumna Adnan; Zubair Ahmad; Hasnain Ahmed Farooqui; Tabish Chawla; S M Adnan Ali
Journal:  Mol Biol Rep       Date:  2021-11-23       Impact factor: 2.316

2.  Cryptotanshinone suppresses tumorigenesis by inhibiting lipogenesis and promoting reactive oxygen species production in KRAS‑activated pancreatic cancer cells.

Authors:  Tokio Terado; Chul Jang Kim; Akiyo Ushio; Kahori Minami; Yukihiro Tambe; Susumu Kageyama; Akihiro Kawauchi; Toshiyuki Tsunoda; Senji Shirasawa; Hiroyuki Tanaka; Hirokazu Inoue
Journal:  Int J Oncol       Date:  2022-07-27       Impact factor: 5.884

3.  Aberrant activation of KRAS in mouse theca-interstitial cells results in female infertility.

Authors:  Penghao Sun; Hongliang Wang; Lingyun Liu; Kaimin Guo; Xian Li; Yin Cao; Chemyong Ko; Zi-Jian Lan; Zhenmin Lei
Journal:  Front Physiol       Date:  2022-08-19       Impact factor: 4.755
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.